In the TM00099 tumor, subclone 1 dominated the non-cisplatin xenografts (70% of cells on average, as interpolated from the LRP1B CN values) while the cisplatin-treated xenografts had reduced levels of subclone 1 (43% of cells on average). This evidence concerns the gene LRP1B and neoplasm.